India Considers Quality Designations For Generics In State Stores
This article was originally published in PharmAsia News
Indian regulators and the pharmaceutical industry are holding discussions about a government proposal to require a quality designation for generic drugs. The discussions are being held relative to government plans to open a network of generics-only pharmacies around the country. As part of that move, regulators want to ensure the network sells only quality generics, but there is no specific system currently in place for monitoring the quality of generics in India. The idea is that a quality mark on a drug would help buyers distinguish between an approved generic and a substandard alternative. (Click here for more
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.